UNITED THERAPEUTICS Corp (UTHR)
United Therapeutics develops and sells drugs for pulmonary arterial hypertension and other rare diseases from its base in Silver Spring, Maryland. It last closed at $584.10 on Nov 17, down 0.64% on the day. The average 12-month price target from 9 analysts is $651.44 (+11.5% from the last close), with a high of $768.00 and a low of $321.00. Analyst consensus is Buy, based on the latest ratings from 9 firms (7 buy, 1 hold, 1 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in UTHR, 57% of them bullish and 43% bearish. In the past 30 days there were 9 dark pool prints totaling $23.8M, the largest $14.5M.
Key Stats
Last 12 monthsNot reported for this period.
From UTHR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 9 analysts who set a price target on UTHR in the past 90 days. The average target is $651.44, with a high of $768.00 and a low of $321.00, compared with the last close of $584.10.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 9 | HC Wainwright & Co. | Assumed coverage | Buy | $660 |
| Nov 5 | TD Cowen | Maintained | Buy | $700 |
| Nov 5 | RBC Capital | Target raised | Buy | $697 → $725 |
| Nov 5 | Wells Fargo | Target lowered | Buy | $738 → $703 |
| Nov 4 | BTIG | Target raised | Buy | $728 → $768 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 8% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the Pivot at $583.66, and the nearest resistance the swing high (Oct 1) at $585.79.
| RSI (14) | 54.54 | Middle of its range | Neutral |
| MACD | 10.81 | Below its signal line | Bearish |
| Stochastic | 54.0 | Middle of its range | Neutral |
| ADX (14) | 19.5 | No clear trend | |
| Williams %R | -52.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -24.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −2.9% | Change over 10 sessions | Bearish |
| ATR (14) | $17.88 | Typical daily range, 3.1% of price |
| RSI (14) | 58.67 | Middle of its range | Neutral |
| MACD | 15.83 | Above its signal line | Bullish |
| Stochastic | 75.9 | Middle of its range | Neutral |
| ADX (14) | 28.8 | Trending up | |
| Williams %R | -20.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 126.2 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +17.5% | Change over 10 sessions | Bullish |
| ATR (14) | $37.05 | Typical daily range, 6.3% of price |
What happened before
See how UTHR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How UTHR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in UTHR in the last 90 days.
Dark Pool
30DUTHR Institutional Ownership
Full report →- ▼367 buying vs 450 selling
- ▲Held by funds +2.0 pts
- ▼Funds holding -39
- ▼Superinvestors: 2 added, 3 cut
- ▲Put/call 0.86 to 0.73
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 846 | 885 | −4.4% |
| In funds' top 10 | 23 | 18 | +27.8% |
| Held by funds | 100.6% | 98.6% | +2.0 pts |
| New / increased | 80 / 287 | 100 / 318 | −12.2% |
| Reduced / sold out | 333 / 117 | 331 / 72 | +11.7% |
| Put/call ratio | 0.73 | 0.86 | −15.2% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UTHR is in one of them and how their past UTHR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered UTHR in an article yet. Here's the latest on the wider market.
UTHR Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Lisa McClainR · MI | Sell | $1K – $15K | Oct 31, 2025 | Nov 21, 2025 | 21 d |
| Lisa McClainR · MI | Sell | $1K – $15K | Oct 30, 2025 | Nov 21, 2025 | 22 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Oct 30, 2025 | Nov 21, 2025 | 22 d |
| Michael McCaulR · TX | Sell | $15K – $50K | Oct 27, 2025 | Nov 10, 2025 | 14 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Jun 11, 2025 | Aug 13, 2025 | 63 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About UNITED THERAPEUTICS
United Therapeutics is a pharmaceutical company based in Silver Spring, Maryland. It develops and sells treatments for rare diseases, mainly pulmonary arterial hypertension, a serious condition that affects the blood vessels in the lungs. Its main products include the Tyvaso DPI and Nebulized Tyvaso inhaled treatments, Remodulin, Orenitram, and Adcirca, which it sells in the United States to specialty pharmaceutical distributors. The company also sells Unituxin for high risk neuroblastoma, a cancer, and is developing treatments for other lung diseases.
- Headquarters
- Silver Spring, MD







